Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 7/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13658195 | 0.87 | ACHE (0.51) | KDRCCNB2CDK1CCNB1GSK3B | |
| SCHEMBL2780156 | 0.85 | KDR (0.37) | KDRPARP1KITFLT1ALDH1A1 | |
| SCHEMBL3049564 | 0.81 | KDR (0.35) | KDRPARP1KITFLT1ALDH1A1 | |
| SCHEMBL10255638 | 0.78 | CCNB2 (0.53) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL3049565 | 0.78 | SPR (0.32) | KDRKITFLT1 | |
| SCHEMBL3060552 | 0.72 | HRH3 (0.39) | KDRPARP1KITFLT1OPRM1 | |
| SCHEMBL14097215 | 0.72 | CA1 (0.45) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL2783628 | 0.71 | PARP1 (0.46) | KDRPARP1ACHEKITFLT1 | |
| SCHEMBL3060198 | 0.70 | KDR (0.39) | KDRPARP1KITFLT1 | |
| SCHEMBL2778696 | 0.69 | KDR (0.40) | KDRPARP1KITFLT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090257999-A1 | Method of preventing contrast-induced nephropathy | INOTEK PHARMACEUTICALS CORPORATION (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090257999-A1 | Method of preventing contrast-induced nephropathy | INOTEK PHARMACEUTICALS CORPORATION (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009088860-A2 | A METHOD OF PREVENTING CONTRAST-INDUCED NEPHROPATHY | INOTEK PHARMACEUTICALS CORPORATION (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090257999-A1 | Method of preventing contrast-induced nephropathy | PARP1, PARP2, PARP3 | KDR 3881/4885CCNB2 3302/4885CDK1 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.